Human CCL7/MCP3 Protein
Catalog No: CCL7-HP001
- Species
- Human
- Expression System
- E.coli
- Tag
- His
Product overview
Recombinant Human CCL7/MCP3 Protein is expressed in E. coli with a His tag at the N-terminus. It contains amino acid residues Gln24-Leu99 (UniProt accession: P80098).
Product Details
- Molecular Aliases
- C-C motif chemokine 7; CCL7; NC28; MCP-3; MCP3; SCYA6; SCYA7; FIC; MARC
- Protein Length
- Gln24-Leu99
- Expression System
- E.coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 10.05 kDa. The protein migrates to 14-17 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human CCL7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CCL7 is greater than 95% as determined by SEC-HPLC.
Background
Chemokine C-C motif ligand 7 (CCL7), a member of CC chemokine subfamily, is known to promote the recruitment of many innate immune cell types including monocytes and neutrophils to sites of bacterial and viral infection and eosinophils and basophils to sites of allergic inflammation. CCL7 upregulation has been associated with many inflammatory settings including infection, cardiovascular disease, and the tumor microenvironment.
References
- Ford J, Hughson A, Lim K, Bardina SV, Lu W, Charo IF, Lim JK, Fowell DJ. CCL7 Is a Negative Regulator of Cutaneous Inflammation Following Leishmania major Infection. Front Immunol. 2019 Jan 8;9:3063. doi: 10.3389/fimmu.2018.03063. PMID: 30671055; PMCID: PMC6331479.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.